G. Clark
Statistics and Probability · Journal of Clinical Oncology · 2000–2023
A researcher in the Science corpus: 9 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Statistics and Probability — 5 citations into it
Whom G. Clark trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- Douglas G. Altman (in Statistics and Probability)
- David Moher (in Statistics and Probability)
Papers from G. Clark's perspective
Ordered by how strongly the researchers G. Clark trusts endorse each paper. Same corpus, a different order for every researcher.
- The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration (Annals of Internal Medicine)
- Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. (Journal of the American Medical Association (JAMA))
- The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. (Clinical Chemistry)
- Prognostic factors in non-small cell lung cancer: a decade of progress. (Chest)
- Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. (Clinical Chemistry)
- Tumor characteristics and clinical outcome of elderly women with breast cancer. (Journal of the National Cancer Institute)
- Molecular Determinants for the Tissue Specificity of SERMs (Science)
- [New guidelines to evaluate the response to treatment in solid tumors]. (Bulletin du Cancer)
- The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. (Journal of the American Podiatric Medical Association (Print))
- A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. (New England Journal of Medicine)
Their papers
- Reporting recommendations for tumor marker prognostic studies. (2005) — 808 citations
- Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (2023) — 1,836 citations
- Erlotinib in previously treated non-small-cell lung cancer. (2005) — 4,948 citations
- Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome (2004) — 859 citations
- Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. (2004) — 1,103 citations
- Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. (2003) — 777 citations
- Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. (2003) — 831 citations
- Revision of the American Joint Committee on Cancer staging system for breast cancer. (2002) — 1,247 citations
- Tumor characteristics and clinical outcome of elderly women with breast cancer. (2000) — 726 citations